NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Forecast, Price & News

$20.35

+0.30 (+1.50%)

(As of 05/26/2023 ET)

Compare

Today's Range: $19.98
▼
$20.48
50-Day Range: $16.06
▼
$21.34
52-Week Range: $12.85
▼
$32.45

Volume: 168,963 shs
Average Volume: 298,918 shs
Market Capitalization: $699.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.22

RAPT Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 102.6% Upside
$41.22 Price Target
Short Interest: Bearish
8.50% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.53
Upright™ Environmental Score
News Sentiment: 1.40
Based on 3 Articles This Week
Insider Trading: Selling Shares
$242,500 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.18) to ($3.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

488th out of 1,012 stocks

Pharmaceutical Preparations Industry

230th out of 495 stocks

3.5

Analyst's Opinion

Consensus Rating
RAPT Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.22, RAPT Therapeutics has a forecasted upside of 102.6% from its current price of $20.35.
Amount of Analyst Coverage
RAPT Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.50% of the outstanding shares of RAPT Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
RAPT Therapeutics has a short interest ratio ("days to cover") of 6.5.
Change versus previous month
Short interest in RAPT Therapeutics has recently increased by 2.10%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
RAPT Therapeutics does not currently pay a dividend.
Dividend Growth
RAPT Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
RAPT Therapeutics has received a 75.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for RAPT Therapeutics is -0.53.

3.6

News and Social Media Coverage

News Sentiment
RAPT Therapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for RAPT Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for RAPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RAPT Therapeutics insiders have sold 410.80% more of their company's stock than they have bought. Specifically, they have bought $47,475.00 in company stock and sold $242,500.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of RAPT Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for RAPT Therapeutics are expected to decrease in the coming year, from ($3.18) to ($3.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RAPT Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RAPT Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RAPT Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About RAPT Therapeutics (NASDAQ:RAPT) Stock

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Stock News Headlines

May 25, 2023 | finance.yahoo.com

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 18, 2023 | americanbankingnews.com

Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Target Price at $41.22

May 28, 2023 | Stansberry Research (Ad)

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks

But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.

May 13, 2023 | msn.com

HC Wainwright & Co. Maintains RAPT Therapeutics (RAPT) Buy Recommendation

May 13, 2023 | americanbankingnews.com

HC Wainwright Trims RAPT Therapeutics (NASDAQ:RAPT) Target Price to $41.00

May 12, 2023 | markets.businessinsider.com

Analyst Expectations for RAPT Therapeutics's Future

May 11, 2023 | benzinga.com

RAPT Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

May 11, 2023 | finanznachrichten.de

RAPT Therapeutics, Inc.: RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 28, 2023 | Stansberry Research (Ad)

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks

But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.

May 11, 2023 | msn.com

Recap: RAPT Therapeutics Q1 Earnings

May 11, 2023 | finance.yahoo.com

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023 | finance.yahoo.com

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

April 25, 2023 | americanbankingnews.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $41.44 Consensus Target Price from Brokerages

April 21, 2023 | americanbankingnews.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider William Ho Sells 5,000 Shares of Stock

April 19, 2023 | americanbankingnews.com

RAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $16.77

April 17, 2023 | msn.com

Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session

April 2, 2023 | americanbankingnews.com

RAPT Therapeutics (NASDAQ:RAPT) Earns "Buy" Rating from HC Wainwright

April 1, 2023 | americanbankingnews.com

RAPT Therapeutics (NASDAQ:RAPT) Shares Down 5.3%

March 30, 2023 | seekingalpha.com

RAPT Therapeutics: Potential Strong Upside Ahead

March 29, 2023 | finance.yahoo.com

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

March 29, 2023 | americanbankingnews.com

Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $41.44

March 26, 2023 | benzinga.com

RAPT Therapeutics, Inc.: Company Investigated by the Portnoy Law Firm

March 24, 2023 | americanbankingnews.com

JPMorgan Chase & Co. Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $42.00

March 24, 2023 | americanbankingnews.com

RAPT Therapeutics (NASDAQ:RAPT) Stock Price Down 4.2% After Analyst Downgrade

March 23, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for RAPT Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:RAPT)

March 22, 2023 | seekingalpha.com

Rapt Therapeutics (RAPT) Investor Presentation -slideshow

March 21, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Company Calendar

Last Earnings: 3/14/2023
Today: 5/28/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RAPT
CUSIP: N/A
CIK: 1673772
Web: www.rapt.com
Phone: (650) 489-9000
Fax: N/A
Employees: 81
Year Founded: 2015

Price Target and Rating

Average Stock Price Forecast: $41.22
High Stock Price Forecast: $48.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +102.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-83,840,000.00
Net Margins: N/A
Pretax Margin: -10,456.09%
Return on Equity: -43.24%
Return on Assets: -39.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.86
Quick Ratio: 10.86

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 456.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.42 per share
Price / Book: 3.17

Miscellaneous

Outstanding Shares: 34,350,000
Free Float: 32,456,000
Market Cap: $699.02 million
Optionable: Not Optionable
Beta: 0.37

Social Links

Key Executives

Brian Russell Wong
President, Chief Executive Officer & Director

Rodney K. B. Young
Chief Financial Officer & Secretary

William Ho
Chief Medical Officer

Dirk G. Brockstedt
Chief Scientific Officer

Jim Farmer
Vice President-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RAPT Stock - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT shares.
View RAPT analyst ratings or view top-rated stocks.
What is RAPT Therapeutics' stock price forecast for 2023?: 8 brokers have issued twelve-month price objectives for RAPT Therapeutics' shares. Their RAPT share price forecasts range from $23.00 to $48.00. On average, they expect the company's stock price to reach $41.22 in the next twelve months. This suggests a possible upside of 102.6% from the stock's current price.
View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts.
How have RAPT shares performed in 2023?: RAPT Therapeutics' stock was trading at $19.80 at the start of the year. Since then, RAPT stock has increased by 2.8% and is now trading at $20.35.
View the best growth stocks for 2023 here.
When is RAPT Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RAPT earnings forecast.
How were RAPT Therapeutics' earnings last quarter?: RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03.
What ETFs hold RAPT Therapeutics' stock?: ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Alger 35 ETF (ATFV), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB).
What is Brian Wong's approval rating as RAPT Therapeutics' CEO?: 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).
When did RAPT Therapeutics IPO?: (RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.
What is RAPT Therapeutics' stock symbol?: RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."
Who are RAPT Therapeutics' major shareholders?: RAPT Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (13.00%), Price T Rowe Associates Inc. MD (9.67%), Perceptive Advisors LLC (6.67%), BlackRock Inc. (6.33%), State Street Corp (4.77%) and Great Point Partners LLC (3.95%). Insiders that own company stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends.
How do I buy shares of RAPT Therapeutics?: Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RAPT Therapeutics' stock price today?: One share of RAPT stock can currently be purchased for approximately $20.35.
How much money does RAPT Therapeutics make?: RAPT Therapeutics (NASDAQ:RAPT) has a market capitalization of $699.02 million and generates $1.53 million in revenue each year. The company earns $-83,840,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.
How can I contact RAPT Therapeutics?: RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rapt.com. The company can be reached via phone at (650) 489-9000 or via email at investors@rapt.com.

This page (NASDAQ:RAPT) was last updated on 5/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial